Results 91 to 100 of about 16,602 (194)

Radiomics and machine learning based on preoperative MRI for predicting extrahepatic metastasis in hepatocellular carcinoma patients treated with transarterial chemoembolization

European Journal of Radiology Open
Purpose: To develop and validate a radiomics machine learning (Rad-ML) model based on preoperative MRI to predict extrahepatic metastasis (EHM) in hepatocellular carcinoma (HCC) patients receiving transarterial chemoembolization (TACE) treatment. Methods:
Gang Peng, Xiaojing Cao, Xiaoyu Huang, Xiang Zhou   +3 more
doaj   +1 more source

Therapeutic Effect Analysis of Radiofrequency Ablation on Transarterial Chemoembolization Postoperative Residual [PDF]

West Indian Medical Journal, 2016
C Shi, B Qiao, Q Yang, B Zheng, X Yu, S Wang   +5 more
openaire   +1 more source

Determination of Risk Factors for Pain After Transarterial Chemoembolization with Drug-Eluting Beads for Hepatocellular Carcinoma

Journal of Pain Research, 2020
Tian-Cheng Wang, Zi-Shu Zhang, Yu-Dong Xiao Department of Radiology, The Second Xiangya Hospital of Central South University, Changsha, Hunan, People’s Republic of ChinaCorrespondence: Yu-Dong Xiao Email xiaoyudong222@csu.edu.cnPurpose: To identify
Wang TC, Zhang ZS, Xiao YD
doaj  

Safety and efficacy assessment of transarterial chemoembolization using drug-eluting beads in patients with hepatocellular carcinoma and arterioportal shunt: a single-center experience

Cancer Management and Research, 2019
Yu-dong Xiao, Cong Ma, Zi-shu Zhang,* Jun Liu* Department of Radiology, The Second Xiangya Hospital of Central South University, Changsha 410011, China *These authors contributed equally to this work Objective: To evaluate the feasibility and ...
Xiao YD, Ma C, Zhang ZS, Liu J
doaj  

Immune checkpoint blockade and transarterial chemoembolization in liver-limited hepatocellular carcinoma: new questions at the dawn of a new era

Journal for ImmunoTherapy of Cancer
Anti-programed cell death protein-1 (PD-1) and anti-programmed cell death 1 ligand 1 (PD-L1) antibodies combined with anti-vascular endothelial growth factor (VEGF) or anti-cytotoxic T lymphocyte antigen 4 (CTLA-4) antibodies are now standard therapeutic
Aruj Dhyani, James J Harding
doaj   +1 more source

Advancing risk stratification in intermediate-stage hepatocellular carcinoma undergoing transarterial chemoembolization: the promise of the NTAA model. [PDF]

Hepatobiliary Surg Nutr
Kobus Z, Yarmohammadi H.
europepmc   +1 more source

Efficacy and safety of local treatments combined with targeted therapy and immunotherapy versus targeted therapy plus immunotherapy alone in hepatocellular carcinoma: A meta-analysis. [PDF]

Medicine (Baltimore)
Zhang S, Tang Y, Mao X, Sheng T.
europepmc   +1 more source

Prevalence of gastrointestinal side effects in hepatocellular carcinoma patients receiving sorafenib: a meta-analysis of 136 studies and 14,416 patients. [PDF]

Ther Adv Med Oncol
Arendt N, Payo-Serafín T, Kolosenko A, Kopsida M, Sjöblom M, Heindryckx F.   +5 more
europepmc   +1 more source

DEB-TACE-HAIC combined with donafenib and camrelizumab in the treatment of unresectable hepatocellular carcinoma: a multicenter retrospective study. [PDF]

Front Immunol
Ma Y, Long J, Shi S, Fang X, Wang R, Xiong F, Ren H, Li W, Zhang X.   +8 more
europepmc   +1 more source

Efficacy and safety of transarterial chemoembolization plus donafenib with or without camrelizumab for unresectable hepatocellular carcinoma: a propensity score matching analysis. [PDF]

Front Immunol
Zhang Q, Lei Z, Qing H, Xie X.
europepmc   +1 more source